PTGX (Protagonist Therapeutics, Inc)
Insider Trading Activity
Every open-market purchase and sale reported by PTGX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-12 | DINESH V PH D PATEL | President and CEO | MIXED | — | — |
| 2026-06-25 | William D. Waddill | Director | MIXED | — | — |
| 2026-06-11 | William D. Waddill | Director | MIXED | — | — |
| 2026-06-01 | William D. Waddill | Director | MIXED | — | — |
| 2026-05-14 | DINESH V PH D PATEL | President and CEO | MIXED | — | — |
| 2026-05-12 | DINESH V PH D PATEL | President and CEO | MIXED | — | — |
| 2026-05-11 | Bryan Giraudo | Director | MIXED | — | — |
| 2026-04-24 | DINESH V PH D PATEL | President and CEO | G | — | — |
| 2026-04-21 | Asif Ali | Chief Financial Officer | Sell | — | — |
| 2026-03-27 | ARTURO MD MOLINA | Chief Medical Officer | MIXED | — | — |
| 2026-03-27 | HAROLD E SELICK | Director | MIXED | — | — |
| 2026-03-27 | Asif Ali | Chief Financial Officer | MIXED | — | — |
| 2026-03-25 | DINESH V PH D PATEL | President and CEO | MIXED | — | — |
| 2026-02-18 | Lewis T Williams | Director | MIXED | — | — |
| 2026-02-06 | William D. Waddill | Director | MIXED | — | — |
| 2026-01-27 | ARTURO MD MOLINA | Chief Medical Officer | MIXED | — | — |
| 2026-01-27 | Asif Ali | Chief Financial Officer | MIXED | — | — |
| 2026-01-27 | DINESH V PH D PATEL | President and CEO | MIXED | — | — |
| 2026-01-21 | Asif Ali | Chief Financial Officer | Sell | — | — |
| 2026-01-21 | DINESH V PH D PATEL | President and CEO | Sell | — | — |
| 2026-01-21 | ARTURO MD MOLINA | Chief Medical Officer | Sell | — | — |
| 2026-01-13 | HAROLD E SELICK | Director | M | — | — |
| 2026-01-06 | Sarah A O'Dowd | Director | A | — | — |
| 2026-01-06 | Bryan Giraudo | Director | A | — | — |
| 2026-01-06 | Asif Ali | Chief Financial Officer | A | — | — |
| 2026-01-06 | DINESH V PH D PATEL | President and CEO | A | — | — |
| 2026-01-06 | William D. Waddill | Director | A | — | — |
| 2026-01-06 | Lewis T Williams | Director | A | — | — |
| 2026-01-06 | ARTURO MD MOLINA | Chief Medical Officer | A | — | — |
| 2026-01-06 | HAROLD E SELICK | Director | A | — | — |
| 2025-11-24 | DINESH V PH D PATEL | President and CEO | G | — | — |
| 2025-11-19 | ARTURO MD MOLINA | Chief Medical Officer | Sell | — | — |
| 2025-10-14 | William D. Waddill | Director | MIXED | — | — |
| 2025-09-24 | William D. Waddill | Director | Sell | — | — |
| 2025-09-18 | DINESH V PH D PATEL | President and CEO | G | — | — |
| 2025-08-29 | William D. Waddill | Director | Sell | — | — |
| 2025-07-28 | DINESH V PH D PATEL | President and CEO | Sell | — | — |
| 2025-07-23 | DINESH V PH D PATEL | President and CEO | MIXED | — | — |
| 2025-07-18 | DINESH V PH D PATEL | President and CEO | G | — | — |
| 2025-06-17 | DINESH V PH D PATEL | President and CEO | G | — | — |
| 2025-06-11 | ARTURO MD MOLINA | Chief Medical Officer | MIXED | — | — |
| 2025-04-30 | HAROLD E SELICK | Director | M | — | — |
| 2025-04-23 | Asif Ali | Chief Financial Officer | Sell | — | — |
| 2025-03-19 | William D. Waddill | Director | Sell | — | — |
| 2025-03-14 | ARTURO MD MOLINA | Chief Medical Officer | MIXED | — | — |
| 2025-03-14 | Asif Ali | Chief Financial Officer | MIXED | — | — |
| 2025-03-05 | DINESH V PH D PATEL | President and CEO | M | — | — |
| 2025-02-20 | DINESH V PH D PATEL | President and CEO | Sell | — | — |
| 2025-01-17 | DINESH V PH D PATEL | President and CEO | F | — | — |
| 2025-01-17 | ARTURO MD MOLINA | Chief Medical Officer | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,449,183 | — |
| — | Director | 2,419,735 | — |
| — | 10%+ Owner | 2,116,552 | — |
| — | 10%+ Owner | 2,099,482 | — |
| — | Director | 1,869,922 | — |
| — | Director | 1,516,149 | — |
| — | President and CEO | 523,478 | — |
| — | Chief Development Officer | 359,611 | — |
| — | Chief Medical Officer | 99,115 | — |
| — | Chief R&D Strategy Officer | 96,603 | — |
| — | Director | 60,845 | — |
| — | Chief Financial Officer | 59,003 | — |
| — | Director | 37,825 | — |
| — | Chief Medical Officer | 32,021 | — |
| — | Chief Financial Officer | 30,560 | — |
| — | Director | 25,825 | — |
| — | Chief Financial Officer | 18,521 | — |
| — | Chief Medical Officer | 14,000 | — |
| — | Director | 7,825 | — |
| — | Director | 7,825 | — |
| — | Director | 3,700 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PTGX quote page; the site-wide leaderboard is on the insider transactions hub.